Compare iShares Silver Trust (SLV) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Silver Trust vs Summit Therapeutics Inc — how do they compare? iShares Silver Trust trades at $54.78 (market cap $29.02B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: iShares Silver Trust is far larger — about 2.1× Summit Therapeutics Inc's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Silver Trust for 89 Days and Summit Therapeutics Inc for 16 Days on average.
| SLV | SMMT | |
|---|---|---|
Market Cap | $29.02B | $13.71B |
Volume | 16,510,334 | 6,173,057 |
52-Week High | $105.57 | $26.38 |
52-Week Low | $42.40 | $12.43 |
Typical Hold Time | 89 Days | 16 Days |
Sector | — | Health |
Enterprise Value | — | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLV trades at $54.78, up 1.78% today, but faces a bearish technical outlook with 18 sell signals versus 4 buy signals. The company reported $2.17M net income for 2024 despite zero revenue, with total assets surging to $13.41B from $10M in 2023. Recent news highlights silver's volatility amid Fed policy uncertainty and rising Treasury yields.
Outlook remains cautious given technical weakness and macroeconomic pressures on precious metals. The asset growth without corresponding revenue generation raises fundamental concerns, while institutional sentiment appears mixed amid silver's recent price decline of nearly 50% from recent highs.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
